Skip to main content

Test Price

2,800 AED

✅ Home Collection Available

C19orf12 Gene (SPG43) Genetic Test in UAE | 2800 AED | DHA Licensed

Executive Summary & Core Metrics

🛡️

Clinical Assurance & Service Highlights

  • ✔ 99.9% Diagnostic Sensitivity – ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
  • ✔ VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Available daily 8 AM to 11 PM.
  • ✔ Telephonic Post-Test Clinical Guidance – Expert interpretation of results with genetic counselling support.
  • ✔ Insurance Direct Billing – Verify coverage via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The C19orf12 gene NGS test detects pathogenic variants in the C19orf12 gene, confirming autosomal recessive hereditary spastic paraplegia type 43 (SPG43). It utilizes next-generation sequencing for comprehensive single-gene analysis, delivering complete exon coverage with >99% sensitivity. This targeted approach reduces turnaround time and avoids incidental findings.

Feature Our Single‑Gene NGS Test Whole Exome Sequencing (WES)
Methodology Targeted Next‑Generation Sequencing Whole Exome Capture & Sequencing
Diagnostic Precision >99.9% analytical sensitivity for C19orf12 High coverage but dependent on target enrichment; may miss deep intronic variants.
Turnaround Time 3 – 4 Weeks 6 – 8 Weeks
Incidental Findings None – analysis limited to C19orf12 gene Risk of secondary/incidental findings outside primary indication.

Physician Insight & Safety Protocols

“As a Consultant Medical Geneticist, I emphasize that any genetic finding must be interpreted within the full clinical picture. A positive C19orf12 variant can confirm SPG43 and guide management, but a negative result does not rule out other hereditary or acquired neurological disorders. Always correlate with physical exam, family history, and neuroimaging.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory Notice – Medication Continuity

⚠ Medication Alert

Do not discontinue any prescribed medication without explicit instruction from your treating physician.

Exclusion Criteria

  • Recent blood transfusion or bone marrow transplant (may interfere with DNA source).
  • Inability to provide a sterile blood sample or dried blood spot due to severe skin condition.
  • Non‑consenting minors – genetic testing must comply with parental consent requirements under UAE Federal Law No. 2 of 2019 and Federal Decree-Law No. 4 of 2016.

Seek emergency care immediately if you experience: sudden loss of mobility, severe muscle spasms, breathing difficulty, or loss of consciousness.

Patient FAQ & Clinical Guidance

1. What is the C19orf12 (SPG43) genetic test and why is it ordered?

This targeted next‑generation sequencing test identifies mutations in the C19orf12 gene, providing a definitive molecular diagnosis for hereditary spastic paraplegia type 43 and informing recurrence risk for family planning.

2. How accurate is the NGS test and how should I prepare?

The test demonstrates >99.9% analytical sensitivity for known pathogenic variants within the C19orf12 coding region, requiring only a standard blood draw or dried blood spot card without fasting.

3. What happens after the test and how will I receive my results?

Results are released within 3–4 weeks via secure electronic delivery, and a complimentary telephonic genetic counselling session is offered to explain the clinical implications.

UAE Regulatory & Data Privacy Adherence

Commitment to Privacy and Security: DNA Labs UAE operates under DHA Facility License No. 1143. All genetic data is handled in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. No genetic information is shared without explicit written consent.

Clinical & Logistical Metadata

Test Name C19orf12 Gene (SPG43) Genetic Test – Targeted NGS
Price (AED) 2,800
Turnaround Time 3 – 4 Weeks
Sample Type / Matrix Whole Blood (EDTA) or Dried Blood Spot (FTA Card) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection
Methodology Used Targeted Next-Generation Sequencing (NGS) – Single Gene Analysis
ICD-10-CM Code G11.4
LOINC Code 83402-5
DHA Facility License & Laboratory Address License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians